阿托伐他汀联合苯扎贝特对急性冠脉综合征患者的调脂效果分析

摘要

目的 探讨阿托伐他汀联合苯扎贝特对急性冠脉综合征患者的调脂效果.方法 选择本院2016年1月至2017年1月收治的106例急性冠脉综合征患者作为研究对象,随机分为观察组和对照组两组,各53例,其中对照组患者采取阿托伐他汀药物治疗,观察组患者在对照组的基础上外加苯扎贝特药物治疗.比较两组患者治疗前后TG、TC、LDL-C以及HDL-C水平,血脂达标率,不良反应发生率的不同.结果 两组患者治疗前血脂水平比较差异无统计学意义(P>0.05),观察组和对照组患者治疗12周以后TG、LDL-C、TC均值明显降低(P<0.05),且观察组患者低于对照组患者(P<0.05);治疗12周以后,观察组HDL-C值明显高于对照组(P<0.05);治疗12周以后,观察组的TG、LDL-C、HDL-C、非HDL-C的达标率均高于对照组(P<0.05);两组患者不良反应发生率比较差异无统计学意义(χ2=0.135,P=0.713).结论 阿托伐他汀联合苯扎贝特对急性冠脉综合征患者调脂效果具有协同作用,疗效显著,安全性好.%Objective To analyze the effect of atorvastatin combined with bezafibrate on the lipid regulation in patients with acute coronary syndrome. Methods 106 patients with acute coronary syndrome treated in our hospital from January 2016 to January 2017 were selected and were randomly divided into the observation group and the control group, 53 cases in each group. The patients in the control group were treated with atorvastatin, and the patients in the observation group were treated with bezafibrate on the basis of the control group. The levels of triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) before and after the treatment, the rate of blood lipid reaching the standard, the incidence of adverse reactions of the two groups were compared. Results There was no statistically significant difference in the level of serum lipid between the two groups before the treatment (P>0.05). The levels of TG, LDL-C, and TC in the observation group and the control group significantly reduced after 12 weeks of treatment (P<0.05), those in the observation group were lower than those in the control group (P<0.05). After 12 weeks of treatment, the level of HDL-C in the observation group was significantly higher than that in the control group (P<0.05); the rates of TG, LDL-C, HDL-C, and non HDL-C reaching the standard in the observation group were higher than those in the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (χ 2=0.135, P=0.713). Conclusion Atorvastatin and bezafibrate have synergistic effect on regulating lipid in patients with acute coronary syndrome, with significant efficacy and safety.